PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
12.91%
Positive revenue growth while AVGO is negative. John Neff might see a notable competitive edge here.
16.69%
Positive gross profit growth while AVGO is negative. John Neff would see a clear operational edge over the competitor.
91.72%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
91.72%
Positive operating income growth while AVGO is negative. John Neff might view this as a competitive edge in operations.
96.98%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
92.00%
Positive EPS growth while AVGO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
92.00%
Positive diluted EPS growth while AVGO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
0.52%
Share change of 0.52% while AVGO is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
-0.10%
Reduced diluted shares while AVGO is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
2281.65%
OCF growth above 1.5x AVGO's 3.24%. David Dodd would confirm a clear edge in underlying cash generation.
464.38%
FCF growth above 1.5x AVGO's 22.03%. David Dodd would verify if the firm’s strategic investments yield superior returns.
80.39%
10Y revenue/share CAGR above 1.5x AVGO's 50.43%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
-1.28%
Negative 5Y CAGR while AVGO stands at 50.43%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
18.76%
3Y revenue/share CAGR above 1.5x AVGO's 5.58%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
22097.04%
10Y OCF/share CAGR above 1.5x AVGO's 151.75%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
-46.36%
Negative 5Y OCF/share CAGR while AVGO is at 151.75%. Joel Greenblatt would question the firm’s operational model or cost structure.
31.30%
3Y OCF/share CAGR at 50-75% of AVGO's 60.69%. Martin Whitman would suspect weaker recent execution or product competitiveness.
1572.42%
Net income/share CAGR above 1.5x AVGO's 417.10% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
-39.06%
Negative 5Y net income/share CAGR while AVGO is 417.10%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
199.84%
3Y net income/share CAGR above 1.5x AVGO's 21.47%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
272.06%
10Y equity/share CAGR 1.25-1.5x AVGO's 199.65%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
74.22%
Below 50% of AVGO's 199.65%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
75.00%
3Y equity/share CAGR at 50-75% of AVGO's 110.51%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
8.31%
AR growth well above AVGO's 1.88%. Michael Burry fears inflated revenue or higher default risk in the near future.
12.98%
Inventory growth well above AVGO's 10.10%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
3.22%
Asset growth at 50-75% of AVGO's 5.08%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
3.34%
Similar to AVGO's 3.69%. Walter Schloss finds parallel capital usage or profit distribution strategies.
-2.85%
We’re deleveraging while AVGO stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-0.95%
Our R&D shrinks while AVGO invests at 2.15%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
12.44%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.